Clinical Trial Update: SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SKB264 in combination with KL-A167 as neoadjuvant therapy for early-stage, high-risk ER+/HER2- breast cancer; the study is not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KL-A167
• SKB264

Snippet

Sponsor: West China Hospital | Conditions: ER+HER2- Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING